PLoS ONE (Jan 2022)

Nicotine has no significant cytoprotective activity against SARS-CoV-2 infection.

  • Fang Zheng,
  • Elena Lian,
  • Gaby Ramirez,
  • Carley McAlister,
  • Shuo Zhou,
  • Wen Zhang,
  • Chunming Liu,
  • Rushika Perera,
  • Chang-Guo Zhan

DOI
https://doi.org/10.1371/journal.pone.0272941
Journal volume & issue
Vol. 17, no. 8
p. e0272941

Abstract

Read online

When coronavirus disease 2019 (COVID-19) became a pandemic, one of most important questions was whether people who smoke are at more risk of COVID-19 infection. A number of clinical data have been reported in the literature so far, but controversy exists in the collection and interpretation of the data. Particularly, there is a controversial hypothesis that nicotine might be able to prevent SARS-CoV-2 infection. In the present study, motivated by the reported controversial clinical data and the controversial hypothesis, we carried out cytotoxicity assays in Vero E6 cells to examine the potential cytoprotective activity of nicotine against SARS-CoV-2 infection and demonstrated for the first time that nicotine had no significant cytoprotective activity against SARS-CoV-2 infection in these cells.